Sensitivity of NOS-dependent vascular relaxation pathway to mineralocorticoid receptor blockade in caveolin-1-deficient mice

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 298, Issue 6, 2010, Pages

  Pojoga, Luminita H ^a   Adamová, Zuzana ^b   Kumar, Abhinav ^b   Stennett, Amanda K ^b   Romero, Jose R ^a   Adler, Gail K ^a   Williams, Gordon H ^a   Khalil, Raouf A ^b  

^a Division of Endocrinology   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Aldosterone; Caveolae; Endothelial nitric oxide synthase; Endothelium; Eplerenone

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; ALDOSTERONE; CAVEOLIN 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EPLERENONE; MINERALOCORTICOID RECEPTOR; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE;

ALDOSTERONE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; ENDOTHELIUM; GENE EXPRESSION; HEART; HEART BLOOD VESSEL; HEART MUSCLE RELAXATION; HIGH SODIUM INTAKE; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYSTOLIC BLOOD PRESSURE; THORACIC AORTA; VASOCONSTRICTION; WESTERN BLOTTING; WILD TYPE;

ACETYLCHOLINE; ALDOSTERONE; ANIMALS; CAVEOLIN 1; MALE; MICE; MICE, KNOCKOUT; MODELS, ANIMAL; MUSCLE RELAXATION; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; PHENYLEPHRINE; RECEPTORS, MINERALOCORTICOID; SIGNAL TRANSDUCTION; SODIUM CHLORIDE, DIETARY; SPIRONOLACTONE; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS; VASODILATION; VASODILATOR AGENTS;

EID: 77952653780     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00661.2009     Document Type: Article

References (75)

1. Adler GK, Williams GH. Aldosterone: villain or protector? Hypertension 50: 31-32, 2007.
2. Albinsson S, Shakirova Y, Rippe A, Baumgarten M, Rosengren BI, Rippe C, Hallmann R, Hellstrand P, Rippe B, Swärd K. Arterial remodeling and plasma volume expansion in caveolin-1-deficient mice. Am J Physiol Regul Integr Comp Physiol 293: R1222-R1231, 2007.
3. Alzamora R, Brown LR, Harvey BJ. Direct binding and activation of protein kinase C isoforms by aldosterone and 17beta-estradiol. Mol Endocrinol 21: 2637-2650, 2007.
4. 2+ signaling in arterial myocytes. Am J Physiol Cell Physiol 278: C163-C173, 2000.
5. Barron LA, Green GM, Khalil RA. Gender differences in vascular smooth muscle reactivity to increases in extracellular sodium salt. Hypertension 39: 425-432, 2002.
6. Batova S, DeWever J, Godfraind T, Balligand JL, Dessy C, Feron O. The calcium channel blocker amlodipine promotes the unclamping of eNOS from caveolin in endothelial cells. Cardiovasc Res 71: 478-485, 2006.
7. Bernier SG, Haldar S, Michel T. Bradykinin-regulated interactions of the mitogen-activated protein kinase pathway with the endothelial nitricoxide synthase. J Biol Chem 275: 30707-30715, 2000.
8. Boo YC, Kim HJ, Song H, Fulton D, Sessa W, Jo H. Coordinated regulation of endothelial nitric oxide synthase activity by phosphorylation and subcellular localization. Free Radic Biol Med 41: 144-153, 2006.
9. Brown NJ. Eplerenone: cardiovascular protection. Circulation 107: 2512-2518, 2003.
10. Caprio M, Newfell BG, la Sala A, Baur W, Fabbri A, Rosano G, Mendelsohn ME, Jaffe IZ. Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion. Circ Res 102: 1359-1367, 2008.
11. Cohen AW, Razani B, Wang XB, Combs TP, Williams TM, Scherer PE, Lisanti MP. Caveolin-1-deficient mice show insulin resistance and defective insulin receptor protein expression in adipose tissue. Am J Physiol Cell Physiol 285: C222-C235, 2003.
12. Davies JI, Band M, Morris A, Struthers AD. Spironolactone impairs endothelial function and heart rate variability in patients with type 2 diabetes. Diabetologia 47: 1687-1694, 2004.
13. de Wardener HE, He FJ, MacGregor GA. Plasma sodium and hypertension. Kidney Int 66: 2454-2466, 2004.
14. Di Zhang A, Cat AN, Soukaseum C, Escoubet B, Cherfa A, Messaoudi S, Delcayre C, Samuel JL, Jaisser F. Cross-talk between mineralocorticoid and angiotensin II signaling for cardiac remodeling. Hypertension 52: 1060-1067, 2008.
15. Drab M, Verkade P, Elger M, Kasper M, Lohn M, Lauterbach B, Menne J, Lindschau C, Mende F, Luft FC, Schedl A, Haller H, Kurzchalia TV. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science 293: 2449-2452, 2001.
16. Drumm K, Kress TR, Gassner B, Krug AW, Gekle M. Aldosterone stimulates activity and surface expression of NHE3 in human primary proximal tubule epithelial cells (RPTEC). Cell Physiol Biochem 17: 21-28, 2006.
17. Feron O, Belhassen L, Kobzik L, Smith TW, Kelly RA, Michel T. Endothelial nitric oxide synthase targeting to caveolae. Specific interactions with caveolin isoforms in cardiac myocytes and endothelial cells. J Biol Chem 271: 22810-22814, 1996.
18. Feron O, Saldana F, Michel JB, Michel T. The endothelial nitric-oxide synthase-caveolin regulatory cycle. J Biol Chem 273: 3125-3128, 1998.
19. Ferrario CM, Strawn WB. Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol 98: 121-128, 2006.
20. Fleming I, Busse R. NO: the primary EDRF. J Mol Cell Cardiol 31: 5-14, 1999.
21. Funder JW. Mineralocorticoid receptors and cardiovascular damage: it's not just aldosterone. Hypertension 47: 634-635, 2006.
22. Funder JW. Reconsidering the roles of the mineralocorticoid receptor. Hypertension 53: 286-290, 2009.
23. Funder JW. Why are mineralocorticoid receptors so nonselective? Curr Hypertens Rep 9: 112-116, 2007.
24. Giardina JB, Green GM, Rinewalt AN, Granger JP, Khalil RA. Role of endothelin B receptors in enhancing endothelium-dependent nitric oxide-mediated vascular relaxation during high salt diet. Hypertension 37: 516-523, 2001.
25. Golestaneh N, Klein C, Valamanesh F, Suarez G, Agarwal MK, Mirshahi M. Mineralocorticoid receptor-mediated signaling regulates the ion gated sodium channel in vascular endothelial cells and requires an intact cytoskeleton. Biochem Biophys Res Commun 280: 1300-1306, 2001.
26. Guyton AC. Blood pressure control - special role of the kidneys and body fluids. Science 252: 1813-1816, 1991.
27. Hall JE. Control of sodium excretion by angiotensin II: intrarenal mechanisms and blood pressure regulation. Am J Physiol Regul Integr Comp Physiol 250: R960-R972, 1986.
28. Holtzman EJ, Braley LM, Williams GH, Hollenberg NK. Kinetics of sodium homeostasis in rats: rapid excretion and equilibration rates. Am J Physiol Regul Integr Comp Physiol 254: R1001-R1006, 1988.
29. Hurwitz S, Fisher ND, Ferri C, Hopkins PN, Williams GH, Hollenberg NK. Controlled analysis of blood pressure sensitivity to sodium intake: interactions with hypertension type. J Hypertens 21: 951-959, 2003.
30. Ignarro LJ. Nitric oxide as a unique signaling molecule in the vascular system: a historical overview. J Physiol Pharmacol 53: 503-514, 2002.
31. Ishizaka N, Griendling KK, Lassegue B, Alexander RW. Angiotensin II type 1 receptor: relationship with caveolae and caveolin after initial agonist stimulation. Hypertension 32: 459-466, 1998.
32. 2+ exchanger type-1 in vascular smooth muscle. Nat Med 10: 1193-1199, 2004.
33. Jernigan NL, Drummond HA. Myogenic vasoconstriction in mouse renal interlobar arteries: role of endogenous β- and γ-ENaC. Am J Physiol Renal Physiol 291: F1184-F1191, 2006.
34. Joffe HV, Adler GK. Effect of aldosterone and mineralocorticoid receptor blockade on vascular inflammation. Heart Fail Rev 10: 31-37, 2005.
35. +. Pflügers Arch 416: 727-734, 1990.
36. Khalil RA. Dietary salt and hypertension: new molecular targets add more spice. Am J Physiol Regul Integr Comp Physiol 290: R509-R513, 2006.
37. Kim KH, Bender JR. Membrane-initiated actions of estrogen on the endothelium. Mol Cell Endocrinol 308: 3-8, 2009.
38. Kosachunhanun N, Hunt SC, Hopkins PN, Williams RR, Jeunemaitre X, Corvol P, Ferri C, Mortensen RM, Hollenberg NK, Williams GH. Genetic determinants of nonmodulating hypertension. Hypertension 42: 901-908, 2003.
39. + channels by aldosterone: role of Sgk1. Clin Exp Pharmacol Physiol 35: 235-241, 2008.
40. Li L, Yang G, Ebara S, Satoh T, Nasu Y, Timme TL, Ren C, Wang J, Tahir SA, Thompson TC. Caveolin-1 mediates testosterone-stimulated survival/clonal growth and promotes metastatic activities in prostate cancer cells. Cancer Res 61: 4386-4392, 2001.
41. Li T, Sotgia F, Vuolo MA, Li M, Yang WC, Pestell RG, Sparano JA, Lisanti MP. Caveolin-1 mutations in human breast cancer: functional association with estrogen receptor alpha-positive status. Am J Pathol 168: 1998-2013, 2006.
42. Martinez DV, Rocha R, Matsumura M, Oestreicher E, Ochoa-Maya M, Roubsanthisuk W, Williams GH, Adler GK. Cardiac damage prevention by eplerenone: comparison with low sodium diet or potassium loading. Hypertension 39: 614-618, 2002.
43. McEneaney V, Harvey BJ, Thomas W. Aldosterone regulates rapid trafficking of epithelial sodium channel subunits in renal cortical collecting duct cells via protein kinase D activation. Mol Endocrinol 22: 881-892, 2008.
44. Menard J. The 45-year story of the development of an antialdosterone more specific than spironolactone. Mol Cell Endocrinol 217: 45-52, 2004.
45. Meneton P, Jeunemaitre X, de Wardener HE, MacGregor GA. Links between dietary salt intake, renal salt handling, blood pressure, and cardiovascular diseases. Physiol Rev 85: 679-715, 2005.
46. Mercier I, Casimiro MC, Zhou J, Wang C, Plymire C, Bryant KG, Daumer KM, Sotgia F, Bonuccelli G, Witkiewicz AK, Lin J, Tran TH, Milliman J, Frank PG, Jasmin JF, Rui H, Pestell RG, Lisanti MP. Genetic ablation of caveolin-1 drives estrogen-hypersensitivity and the development of DCIS-like mammary lesions. Am J Pathol 174: 1172-1190, 2009.
47. Minshall RD, Sessa WC, Stan RV, Anderson RG, Malik AB. Caveolin regulation of endothelial function. Am J Physiol Lung Cell Mol Physiol 285: L1179-L1183, 2003.
48. Murad Shattuck Lecture F. Nitric oxide and cyclic GMP in cell signaling and drug development. N Engl J Med 2006; 355(19): 2003-2011
49. i in vascular smooth muscle cells of female rat. Am J Physiol Cell Physiol 278: C834-C844, 2000.
50. Mutoh A, Isshiki M, Fujita T. Aldosterone enhances ligand-stimulated nitric oxide production in endothelial cells. Hypertens Res 31: 1811-1820, 2008.
51. Oestreicher EM, Martinez-Vasquez D, Stone JR, Jonasson L, Roubsanthisuk W, Mukasa K, Adler GK. Aldosterone and not plasminogen activator inhibitor-1 is a critical mediator of early angiotensin II/NG-nitro-L-arginine methyl ester-induced myocardial injury. Circulation 108: 2517-2523, 2003.
52. Oliverio MI, Best CF, Smithies O, Coffman TM. Regulation of sodium balance and blood pressure by the AT1A receptor for angiotensin II. Hypertension 35: 550-554, 2000.
53. Orshal JM, Khalil RA. Gender, sex hormones, and vascular tone. Am J Physiol Regul Integr Comp Physiol 286: R233-R249, 2004.
54. Payne JA, Alexander BT, Khalil RA. Decreased endothelium-dependent NO-cGMP vascular relaxation and hypertension in growth-restricted rats on a high-salt diet. Hypertension 43: 420-427, 2004.
55. Pojoga LH, Romero JR, Yao TM, Loutraris P, Ricchiuti V, Coutinho P, Guo C, Lapointe N, Stone JR, Adler GK, Williams GH. Caveolin-1 ablation reduces the adverse cardiovascular effects of L-NAME and angiotensin II. Endocrinology 151: 1236-1246, 2010.
56. Pojoga LH, Yao TM, Sinha S, Ross RL, Lin JC, Raffetto JD, Adler GK, Williams GH, Khalil RA. Effect of dietary sodium on vasoconstriction and eNOS-mediated vascular relaxation in caveolin-1-deficient mice. Am J Physiol Heart Circ Physiol 294: H1258-H1265, 2008.
57. Ponnuchamy B, Khalil RA. Cellular mediators of renal vascular dysfunction in hypertension. Am J Physiol Regul Integr Comp Physiol 296: R1001-R1018, 2009.
58. Razani B, Engelman JA, Wang XB, Schubert W, Zhang XL, Marks CB, Macaluso F, Russell RG, Li M, Pestell RG, Di Vizio D, Hou H Jr, Kneitz B, Lagaud G, Christ GJ, Edelmann W, Lisanti MP. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J Biol Chem 276: 38121-38138, 2001.
59. Rocha R, Stier CT Jr, Kifor I, Ochoa-Maya MR, Rennke HG, Williams GH, Adler GK. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 141: 3871-3878, 2000.
60. Schiffrin EL. Effects of aldosterone on the vasculature. Hypertension 47: 312-318, 2006.
61. 2+-ATPase, and inositol trisphosphate receptor. Proc Natl Acad Sci USA 92: 1759-1763, 1995.
62. Segal SS, Brett SE, Sessa WC. Codistribution of NOS and caveolin throughout peripheral vasculature and skeletal muscle of hamsters. Am J Physiol Heart Circ Physiol 277: H1167-H1177, 1999.
63. Shakirova Y, Bonnevier J, Albinsson S, Adner M, Rippe B, Broman J, Arner A, Swärd K. Increased Rho activation and PKC-mediated smooth muscle contractility in the absence of caveolin-1. Am J Physiol Cell Physiol 291: C1326-C1335, 2006.
64. Smith L, Payne JA, Sedeek MH, Granger JP, Khalil RA. Endothelin-induced increases in Ca2+ entry mechanisms of vascular contraction are enhanced during high-salt diet. Hypertension 41: 787-793, 2003.
65. Stan RV, Roberts WG, Predescu D, Ihida K, Saucan L, Ghitescu L, Palade GE. Immunoisolation and partial characterization of endothelial plasmalemmal vesicles (caveolae). Mol Biol Cell 8: 595-605, 1997.
66. Strawn WB. Eplerenone antagonizes atherosclerosis, but what is the agonist? Hypertension 46: 1093-1094, 2005.
67. Struthers A, Krum H, Williams GH. A comparison of the aldosterone blocking agents eplerenone and spironolactone. Clin Cardiol 31: 153-158, 2008.
68. Turchin A, Guo CZ, Adler GK, Ricchiuti V, Kohane IS, Williams GH. Effect of acute aldosterone administration on gene expression profile in the heart. Endocrinology 147: 3183-3189, 2006.
69. Ushio-Fukai M, Alexander RW. Caveolin-dependent angiotensin II type 1 receptor signaling in vascular smooth muscle. Hypertension 48: 797-803, 2006.
70. 1 receptor signaling in vascular smooth muscle: role in vascular hypertrophy. Circ Res 97: 829-836, 2005.
71. Wunderlich C, Schober K, Lange SA, Drab M, Braun-Dullaeus RC, Kasper M, Schwencke C, Schmeisser A, Strasser RH. Disruption of caveolin-1 leads to enhanced nitrosative stress and severe systolic and diastolic heart failure. Biochem Biophys Res Commun 340: 702-708, 2006.
72. Yu J, Bergaya S, Murata T, Alp IF, Bauer MP, Lin MI, Drab M, Kurzchalia TV, Stan RV, Sessa WC. Direct evidence for the role of caveolin-1 and caveolae in mechanotransduction and remodeling of blood vessels. J Clin Invest 116: 1284-1291, 2006.
73. Zhao YY, Liu Y, Stan RV, Fan L, Gu Y, Dalton N, Chu PH, Peterson K, Ross J Jr, Chien KR. Defects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout mice. Proc Natl Acad Sci USA 99: 11375-11380, 2002.
74. Zhou ZH, Bubien JK. Nongenomic regulation of ENaC by aldosterone. Am J Physiol Cell Physiol 281: C1118-C1130, 2001.
75. Zuo L, Ushio-Fukai M, Ikeda S, Hilenski L, Patrushev N, Alexander RW. Caveolin-1 is essential for activation of Rac1 and NAD(P)H oxidase after angiotensin II type 1 receptor stimulation in vascular smooth muscle cells: role in redox signaling and vascular hypertrophy. Arterioscler Thromb Vasc Biol 25: 1824-1830, 2005.